Hay un gran avance en el desarrollo de fármacos para tumores cerebrales infantiles. Los tumores cerebrales infantiles son una enfermedad maligna más común en los niños. Investigaciones recientes han descubierto que un nuevo fármaco cóctel puede tratar los tumores cerebrales infantiles comunes.
Cancer Cell” magazine recently announced that in the UK, about 400 children develop brain los tumores each year, of which the prevalence of boys is slightly higher than that of girls.
Are we able to take advantage of the results of tumor gene testing and tailor-made treatments, a strategy often referred to as personalized medicine? This treatment strategy can produce very good results for patients with brain tumors.
Neural myeloblastoma (medulloblastoma) is one of the most common tumores malignos of the cerebellum. This Tumor cerebral grows rapidly and most often occurs in children around the age of 5. Las opciones de tratamiento include surgery, radiation, and chemotherapy. Although great progress has been made in treatment methods and techniques, the success rate of treating myeloblastoma still lags far behind other children’s malignancies. In particular, myeloblastoma is a highly aggressive malignancy. Only 40% of patients with meduloblastoma survive, compared with other tumors of a less severe type-with a survival rate of more than 80%.
Researchers in the United States have discovered a new combination therapy for the treatment of highly aggressive neuroblastoma. In laboratory tests, the drug killed células cancerosas cells without any toxicity to normal cells, and researchers hope to conduct clinical trials of the drug. Robert Wechsler-Reya, an adjunct professor at the Sanford Burnham Prebys Medical Institute, said: “Our goal is to confirm that the drug has low toxicity properties. Because doctors and patients in this case urgently require new clinical treatment options, we will soon apply the drug from the laboratory to clinical treatment.
Al combinarse con otros fármacos, se seleccionan in vitro e in vivo nuevos compuestos que inhiben los tumores.
Los ensayos clínicos for neuroblastoma are often very challenging because of the limited number of patients. In addition, coupled with the variability of the disease, most treatments are only effective for one subtype of patient. Understanding which patients will respond to this treatment is one of the main goals of the trial.
"Si podemos desarrollar tratamientos a medida basados en genes tumorales, una estrategia comúnmente conocida como tratamiento individualizado, esto podría traer un gran evangelio a los pacientes con ciertos tumores".
Hay cuatro tipos distintos de neuroblastoma y los pacientes con un tercer grupo de tumores tienen el peor pronóstico: solo el 40% de los pacientes sobreviven a largo plazo. Por el contrario, la supervivencia a largo plazo de otros neuroblastomas es relativamente optimista y alrededor del 80% de los pacientes pueden sobrevivir a largo plazo.
La mayoría del tercer grupo de pacientes con neuroblastoma tiene una alta expresión del oncogén MYC, que es la causa de la división celular incontrolable y la formación de tumores.
There was a study on mice with a third type of neural tube cell tumors that showed histone deacetylase inhibitors (HDACIs) and phosphatidylinositol 3-kinase inhibitors (PI3KIs) might stop mice and people from making neurotubular glioblastomas without doing too much damage to normal cells.
We found several histone deacetylase inhibitors that can kill MYC oncogene-activated neural tube cell tumors without harming normal cell agents (HDACIs),” said Pei Yanxin, an assistant professor at the National Children’s Centro Médico en Washington, DC
The most effective of these compounds is panobinostat, which has entered clinical trials in other tipos de cancer, but has not yet been tested on neuroblastoma.” Dr. Kun-Wei, a postdoctoral researcher at Stanford University, added: “Several other studies have revealed that the mechanism of action of panobinostat is to promote the activation of the FOXO1 gene that can interfere with the oncogenes of MYC.
Phosphatidylinositol 3-kinase inhibitors (PI3KIs) are also thought to have the effect of activating the FOXO1 gene. We hypothesized that panobinostat and phosphatidylinositol 3-kinase inhibitors (PI3KIs) could work together to block Cancer Cell supervivencia.
“It is true that the combined treatment of these two drugs can significantly increase the survival of patients with tumors carrying the MYC gene compared to using a single drug alone.”
